Gynaecological Cancers
Biology and Therapeutics
Herausgeber: Edmondson, Richard; Kehoe, Sean; Gore, Martin
Gynaecological Cancers
Biology and Therapeutics
Herausgeber: Edmondson, Richard; Kehoe, Sean; Gore, Martin
- Broschiertes Buch
- Merkliste
- Auf die Merkliste
- Bewerten Bewerten
- Teilen
- Produkt teilen
- Produkterinnerung
- Produkterinnerung
This book provides comprehensive coverage of gynaecological malignancies based on the 60th RCOG Study Group.
Andere Kunden interessierten sich auch für
- Variability in Human Fertility52,99 €
- Brian DaleFertilization63,99 €
- R. Bentley / C. G. Mascie-Taylor (eds.)Infertility in the Modern World64,99 €
- Ovulation Induction110,99 €
- Joni Stuart CazeauThe Luteal Phase Defect: A Physician's Story of Recurrent Miscarriages to Successful Pregnancy18,99 €
- Gynaecological Oncology for the Mrcog and Beyond62,99 €
- Reproductive Technologies131,99 €
-
-
-
This book provides comprehensive coverage of gynaecological malignancies based on the 60th RCOG Study Group.
Hinweis: Dieser Artikel kann nur an eine deutsche Lieferadresse ausgeliefert werden.
Hinweis: Dieser Artikel kann nur an eine deutsche Lieferadresse ausgeliefert werden.
Produktdetails
- Produktdetails
- Verlag: Cambridge University Press
- Seitenzahl: 272
- Erscheinungstermin: 6. Dezember 2013
- Englisch
- Abmessung: 234mm x 156mm x 16mm
- Gewicht: 468g
- ISBN-13: 9781906985448
- ISBN-10: 1906985448
- Artikelnr.: 39543514
- Verlag: Cambridge University Press
- Seitenzahl: 272
- Erscheinungstermin: 6. Dezember 2013
- Englisch
- Abmessung: 234mm x 156mm x 16mm
- Gewicht: 468g
- ISBN-13: 9781906985448
- ISBN-10: 1906985448
- Artikelnr.: 39543514
Part I. Biology of Gynaecological Cancers: Our Current Understanding: 1.
Morphological sub-types of ovarian carcinoma: new developments and
pathogenesis W. Glenn McCluggage; 2. Novel treatment strategies for
targeting genetic changes in endometrial cancer Susana Banerjee; 3.
Epigenetic biomarkers in ovarian cancer Robert Brown and Janet Graham; 4.
Predictive biology of ovarian cancer Christine A. Parkinson and James D.
Brenton; Part II. The Translation of Biology to the Clinic: 5. Biology of
BRCA1 and BRCA2 genes and implications for cancer management Timothy A.
Yap, Yvette Drew and Susan Shanley; 6. Implications of homologous
recombination defectiveness in ovarian cancer Richard J. Edmondson, Asima
Mukhopadhyay, Aiste Cerbinskaite and Nicola J. Curtin; 7. The future of
PARP inhibitors in the treatment of cancer Yvette Drew, Timothy A. Yap and
Stan B. Kaye; Part III. Imaging and Therapy: State of the Art: 8. The role
of robotics and the future Tim Mould; 9. 'Ultra-radical' surgery in
advanced ovarian cancer Oliver Zivanovic and Dennis S. Chi; 10.
Antivascular therapy in gynaecological cancers Leena Mukherjee and Gordon
Rustin; 11. Oncolytic viral gene therapy in ovarian cancer Iain A. McNeish;
12. Endometrial cancer: what have the clinical trials taught us? Andrew
Clamp; 13. Targeting therapies in cancer: opportunities in ovarian cancer
Ahmed Ashour Ahmed, Stefan Knapp, Anil K. Sood and Robert C. Bast Jr; 14.
Functional imaging: from tumour biology to the clinic Nandita M. deSouza,
Evis Sala, Stavroula Kyriazi and Andrea Rockall; Part IV. What Questions
Are Being Asked by Current Clinical Trials?: 15. Current clinical trials in
ovarian cancer Christina Fotopoulou, Angus McIndoe, Jalid Sehouli and Hani
Gabra; 16. Clinical trials in cervical cancer Karen Tipples and Melanie
Powell; 17. Clinical trials in vulval cancer Tito Lopes; Part V. Consensus
Views: 18. Consensus views arising from the 60th Study Group:
Gynaecological Cancers: Biology and Therapeutics; Index.
Morphological sub-types of ovarian carcinoma: new developments and
pathogenesis W. Glenn McCluggage; 2. Novel treatment strategies for
targeting genetic changes in endometrial cancer Susana Banerjee; 3.
Epigenetic biomarkers in ovarian cancer Robert Brown and Janet Graham; 4.
Predictive biology of ovarian cancer Christine A. Parkinson and James D.
Brenton; Part II. The Translation of Biology to the Clinic: 5. Biology of
BRCA1 and BRCA2 genes and implications for cancer management Timothy A.
Yap, Yvette Drew and Susan Shanley; 6. Implications of homologous
recombination defectiveness in ovarian cancer Richard J. Edmondson, Asima
Mukhopadhyay, Aiste Cerbinskaite and Nicola J. Curtin; 7. The future of
PARP inhibitors in the treatment of cancer Yvette Drew, Timothy A. Yap and
Stan B. Kaye; Part III. Imaging and Therapy: State of the Art: 8. The role
of robotics and the future Tim Mould; 9. 'Ultra-radical' surgery in
advanced ovarian cancer Oliver Zivanovic and Dennis S. Chi; 10.
Antivascular therapy in gynaecological cancers Leena Mukherjee and Gordon
Rustin; 11. Oncolytic viral gene therapy in ovarian cancer Iain A. McNeish;
12. Endometrial cancer: what have the clinical trials taught us? Andrew
Clamp; 13. Targeting therapies in cancer: opportunities in ovarian cancer
Ahmed Ashour Ahmed, Stefan Knapp, Anil K. Sood and Robert C. Bast Jr; 14.
Functional imaging: from tumour biology to the clinic Nandita M. deSouza,
Evis Sala, Stavroula Kyriazi and Andrea Rockall; Part IV. What Questions
Are Being Asked by Current Clinical Trials?: 15. Current clinical trials in
ovarian cancer Christina Fotopoulou, Angus McIndoe, Jalid Sehouli and Hani
Gabra; 16. Clinical trials in cervical cancer Karen Tipples and Melanie
Powell; 17. Clinical trials in vulval cancer Tito Lopes; Part V. Consensus
Views: 18. Consensus views arising from the 60th Study Group:
Gynaecological Cancers: Biology and Therapeutics; Index.
Part I. Biology of Gynaecological Cancers: Our Current Understanding: 1.
Morphological sub-types of ovarian carcinoma: new developments and
pathogenesis W. Glenn McCluggage; 2. Novel treatment strategies for
targeting genetic changes in endometrial cancer Susana Banerjee; 3.
Epigenetic biomarkers in ovarian cancer Robert Brown and Janet Graham; 4.
Predictive biology of ovarian cancer Christine A. Parkinson and James D.
Brenton; Part II. The Translation of Biology to the Clinic: 5. Biology of
BRCA1 and BRCA2 genes and implications for cancer management Timothy A.
Yap, Yvette Drew and Susan Shanley; 6. Implications of homologous
recombination defectiveness in ovarian cancer Richard J. Edmondson, Asima
Mukhopadhyay, Aiste Cerbinskaite and Nicola J. Curtin; 7. The future of
PARP inhibitors in the treatment of cancer Yvette Drew, Timothy A. Yap and
Stan B. Kaye; Part III. Imaging and Therapy: State of the Art: 8. The role
of robotics and the future Tim Mould; 9. 'Ultra-radical' surgery in
advanced ovarian cancer Oliver Zivanovic and Dennis S. Chi; 10.
Antivascular therapy in gynaecological cancers Leena Mukherjee and Gordon
Rustin; 11. Oncolytic viral gene therapy in ovarian cancer Iain A. McNeish;
12. Endometrial cancer: what have the clinical trials taught us? Andrew
Clamp; 13. Targeting therapies in cancer: opportunities in ovarian cancer
Ahmed Ashour Ahmed, Stefan Knapp, Anil K. Sood and Robert C. Bast Jr; 14.
Functional imaging: from tumour biology to the clinic Nandita M. deSouza,
Evis Sala, Stavroula Kyriazi and Andrea Rockall; Part IV. What Questions
Are Being Asked by Current Clinical Trials?: 15. Current clinical trials in
ovarian cancer Christina Fotopoulou, Angus McIndoe, Jalid Sehouli and Hani
Gabra; 16. Clinical trials in cervical cancer Karen Tipples and Melanie
Powell; 17. Clinical trials in vulval cancer Tito Lopes; Part V. Consensus
Views: 18. Consensus views arising from the 60th Study Group:
Gynaecological Cancers: Biology and Therapeutics; Index.
Morphological sub-types of ovarian carcinoma: new developments and
pathogenesis W. Glenn McCluggage; 2. Novel treatment strategies for
targeting genetic changes in endometrial cancer Susana Banerjee; 3.
Epigenetic biomarkers in ovarian cancer Robert Brown and Janet Graham; 4.
Predictive biology of ovarian cancer Christine A. Parkinson and James D.
Brenton; Part II. The Translation of Biology to the Clinic: 5. Biology of
BRCA1 and BRCA2 genes and implications for cancer management Timothy A.
Yap, Yvette Drew and Susan Shanley; 6. Implications of homologous
recombination defectiveness in ovarian cancer Richard J. Edmondson, Asima
Mukhopadhyay, Aiste Cerbinskaite and Nicola J. Curtin; 7. The future of
PARP inhibitors in the treatment of cancer Yvette Drew, Timothy A. Yap and
Stan B. Kaye; Part III. Imaging and Therapy: State of the Art: 8. The role
of robotics and the future Tim Mould; 9. 'Ultra-radical' surgery in
advanced ovarian cancer Oliver Zivanovic and Dennis S. Chi; 10.
Antivascular therapy in gynaecological cancers Leena Mukherjee and Gordon
Rustin; 11. Oncolytic viral gene therapy in ovarian cancer Iain A. McNeish;
12. Endometrial cancer: what have the clinical trials taught us? Andrew
Clamp; 13. Targeting therapies in cancer: opportunities in ovarian cancer
Ahmed Ashour Ahmed, Stefan Knapp, Anil K. Sood and Robert C. Bast Jr; 14.
Functional imaging: from tumour biology to the clinic Nandita M. deSouza,
Evis Sala, Stavroula Kyriazi and Andrea Rockall; Part IV. What Questions
Are Being Asked by Current Clinical Trials?: 15. Current clinical trials in
ovarian cancer Christina Fotopoulou, Angus McIndoe, Jalid Sehouli and Hani
Gabra; 16. Clinical trials in cervical cancer Karen Tipples and Melanie
Powell; 17. Clinical trials in vulval cancer Tito Lopes; Part V. Consensus
Views: 18. Consensus views arising from the 60th Study Group:
Gynaecological Cancers: Biology and Therapeutics; Index.